WOMEN’S HEALTH · PATIENT AND CLINICIAN UPDATE

Women’s Health
Clinical Update

9 October 2026

This week’s most useful message is that pregnancy history matters long after delivery. New evidence also highlights the value of structured postpartum support, the need to check contraception alongside antiseizure medicines, and the limits of a promising early-pregnancy blood marker.

6 OCTOBER · PEER-REVIEWED LONGITUDINAL STUDY

Pregnancy complications can signal later heart, kidney and metabolic risk

Clinical question and result. Do pregnancy complications identify women at higher risk of later cardiovascular disease, type 2 diabetes, hypertension or chronic kidney disease? Researchers followed more than 1.4 million women in English health records for an average of four years. Gestational hypertension and pre-eclampsia were associated with more than three times the later rate of hypertension and approximately twice the rate of chronic kidney disease. Gestational diabetes and several other adverse pregnancy outcomes also identified higher-risk groups.

Evidence strength and limitations. This is a very large, peer-reviewed, real-world cohort with adjustment for established risk factors. It remains observational: coding may be incomplete, unmeasured factors may explain part of the association, and the study does not prove that a particular screening programme prevents events.

Practical implication. A history of gestational diabetes, high blood pressure in pregnancy, pre-eclampsia, preterm birth, placental abruption, stillbirth or a baby unusually small or large for gestational age should not disappear from the medical record after delivery. Clinicians should use it to prompt appropriate blood-pressure, glucose, lipid, kidney-risk and lifestyle assessment according to local guidance.

Verdict: Change practice now—take a complete pregnancy history and use it in long-term risk review. Do not invent new test intervals outside national guidance.

Read the BMJ Medicine study →

2 OCTOBER · PEER-REVIEWED RANDOMISED CLINICAL TRIAL

A trained navigator improved several parts of postpartum care

Clinical question and result. Can one year of personalised patient navigation improve care after childbirth for people facing financial barriers? In a US trial of 405 participants, receiving all six intended care components remained uncommon and was not significantly better with navigation (9.4% versus 7.9%). However, navigation improved postpartum-visit completion (96% versus 80%), depression screening and care (86% versus 72%), anticipatory guidance and several one-year preventive-care measures.

Evidence strength and limitations. Randomisation strengthens confidence that navigation caused the service-use improvements. The primary outcome was negative, the study was conducted at one US academic centre during the pandemic, and it was not designed to detect reductions in serious maternal illness or death.

Practical implication. A simple postpartum register, named staff member, reminder call, depression screen, family-planning check and clear route into primary care may help women remain connected to care. South African services should adapt the principle to available staff rather than copying an expensive programme.

Verdict: Improve postpartum follow-up processes now where feasible, while monitoring whether women actually receive the intended care.

Read the JAMA Health Forum trial →

7 OCTOBER · PEER-REVIEWED PRESCRIPTION-CLAIMS STUDY

Contraception and antiseizure medicines require an interaction check

Clinical question and result. How often are hormonal contraceptives prescribed at the same time as enzyme-inducing antiseizure medicines that can reduce contraceptive effectiveness? Among 21,923 US Medicaid beneficiaries with epilepsy who received both medicine types, 7,154 (32.6%) had a potentially important overlap lasting at least 14 days; the average overlap was about seven months.

Evidence strength and limitations. The large, peer-reviewed analysis identifies a substantial prescribing-safety gap. Claims data cannot show whether medicines were taken, whether counselling occurred or whether pregnancies resulted. The US Medicaid population and prescribing patterns may not represent South Africa, Ireland or the UK.

Practical implication. Clinicians should check the full medication list before prescribing or renewing contraception for anyone taking antiseizure treatment and select a method compatible with the specific medicine and current national guidance. Patients should not stop antiseizure medicine suddenly; they should request a medication and contraception review.

Verdict: Change the prescribing check now. The new study supports safer review rather than a new contraceptive method for everyone.

Read the Neurology study →

5 OCTOBER · PEER-REVIEWED PROSPECTIVE COHORT

First-trimester PlGF is associated with preterm birth, but prediction remains weak

Clinical question and result. Can placental growth factor measured at 11 to 13 weeks help predict preterm birth? In a single-centre Chinese cohort of 1,448 singleton pregnancies, 80 women delivered before 37 weeks. Lower PlGF was associated with higher risk, but adding it to clinical factors improved the model’s discrimination only from an area under the curve of 0.590 to 0.684—still insufficient for dependable individual prediction.

Evidence strength and limitations. Prospective measurement is a strength, but this was an observational, single-centre study with only 80 events and no external validation. Association does not show that PlGF-guided treatment improves outcomes.

Practical implication. Do not offer a stand-alone PlGF test as a reliable preterm-birth prediction test. Continue established antenatal risk assessment, indicated ultrasound and cervical-length pathways, and urgent assessment of concerning symptoms.

Verdict: Watch—routine practice remains unchanged until diverse validation and evidence of clinical benefit are available.

Read the International Journal of Gynecology & Obstetrics study →

MOST WORTH READING · RANKED

Four papers for practice

Evidence window: material newly published or identified since the 2 October briefing. All four selections are peer-reviewed; no preprints or conference-only claims are included. No comparably important new NICE, Irish HSE or South African national women’s-health guideline was verified this week. Educational summary only; it does not replace individual assessment or local clinical guidance.

Earlier briefing: 2 October. Previous editions remain available through their original links.